Liminal BioSciences Inc. (NASDAQ:LMNL) (“Liminal BioSciences” or the “Company”), announced that a consolidation of all of the issued and outstanding common shares of the Company (“Common Shares”) on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Share Consolidation”), will become effective at the opening of trading on February 1, 2023 (the “Effective Date”). The Company’s current trading symbol will remain unchanged. The Consolidation was previously approved by the Company’s shareholders at the special meeting of the shareholders held on January 20, 2023.
Abercrombie’ Peak Holiday Period Hit By Inventory Receipt Slides; Post-Holiday Sales Trend Accelerates
Abercrombie & Fitch Co (NYSE:ANF) expects fiscal 2021 sales growth of 19% – 20% year-on-year and up 2% – 3% compared…
